PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

May 6, 2010 | ISSUE NUMBER 147 VOL 8

FDA
InterMune Denied Approval for Lung Treatment
Feds reject InterMune’s lung disease drug and request additional clinical trials. The cost to InterMune: instant stock crash and questions about the future of the treatment.

Sales
Pfizer and Merck: Bullets Dodged
In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results.

Safety
FDA to Review Prostate Cancer Meds
FDA is reviewing whether a certain class of prostate cancer drugs could lead to diabetes, stroke, death, or heart problems.

Marketing
Do You Have a Head of Social Media?
And do you need one? Julian Upton looks at some of the contrasting ideas that emerged from last month’s Digital Pharma Europe event.

R&D
Managing the Three Drivers of Risk in Drug Development
Re-examining service provider roles can bring safety and speed on the road to registration.

// Merck upped Ken Frazier to president. He had been president of Global Human Health worldwide sales and marketing. // PharmAthene appointed Mitchel Sayare to its board. // Michael Marine joined the Sabine Vaccine Institute as CEO. // Interleukin Genetics added William Mills to its board. // Rigel Pharmaceuticals was named one of the recipients of the 2010 Innovators Award of Excellence by the San Mateo County Economic Development Association. // VIVUS appointed Michael Miller SVP and CCO. // Simbionix added Glen Mayfield and Raanan Cohen to its board. // PharmAthene’s board upped Eric Richman to interim CEO. // China Medicine appointed Fred Wai-Kuen Cheung its new CFO. // Chimerix promoted Kenneth Moch from COO to president and CEO and added him to its board. The company also named George Painter chief scientific officer and chairman of the board. // Genecor CEO Tjerk de Ruiter was elected chair of the industrial and environmental section of BIO, as well as its board. // Fran Dramis joined US Oncology’s board. //

May 20 21 CFR Part 11, Computer Systems Validation and the Requirements of the FDA
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/csv

May 26 Moving Beyond Document Management to Enterprise Content Compliance
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/moving

May 24–27 Contract Lifecycle Management– I-many Summit 2010 User Conference
Miami, FL

June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC

Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA

Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA

Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA

Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy?

Roche To Train Healthcare Workers In Africa's Fight Against Cancer

Merck Announces Senior Management Appointments

Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra

AstraZeneca: Unwitting Advocate for Disclosure?

Follow Pharm Exec on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.